Share on LinkedInShare on LinkedIn

ARTICLE · 18 AUGUST 2014

FDA Receives Second Biosimilar Application

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

Celltrion has announced that it completed the second biosimilar application for its monoclonal antibody infliximab on August 8, 2014.

United StatesGovernment, Public Sector

Celltrion has announced that it completed the second biosimilar application for its monoclonal antibody infliximab on August 8, 2014. Click here for a Jones Day Commentary on the new biosimilar application process.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from